Bence Sipos

List of Publications by Year
in descending order

54 papers	5,186 citations	159585 30 h-index	168389 53 g-index
56 all docs	56 docs citations	56 times ranked	9532 citing authors

#	Article	IF	Citations
1	Stat3/Socs3 Activation by IL-6 Transsignaling Promotes Progression of Pancreatic Intraepithelial Neoplasia and Development of Pancreatic Cancer. Cancer Cell, 2011, 19, 456-469.	16.8	754
2	EGF Receptor Is Required for KRAS-Induced Pancreatic Tumorigenesis. Cancer Cell, 2012, 22, 304-317.	16.8	445
3	Combined inhibition of BET family proteins and histone deacetylases as a potential epigenetics-based therapy for pancreatic ductal adenocarcinoma. Nature Medicine, 2015, 21, 1163-1171.	30.7	349
4	Genetic profile of 22 pancreatic carcinoma cell lines. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2001, 439, 798-802.	2.8	308
5	A comprehensive characterization of pancreatic ductal carcinoma cell lines: towards the establishment of an in vitro research platform. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2003, 442, 444-452.	2.8	284
6	Necroptosis microenvironment directs lineage commitment in liver cancer. Nature, 2018, 562, 69-75.	27.8	283
7	In vivo RNAi screening identifies a mechanism of sorafenib resistance in liver cancer. Nature Medicine, 2014, 20, 1138-1146.	30.7	242
8	Tumor Stroma Interactions Induce Chemoresistance in Pancreatic Ductal Carcinoma Cells Involving Increased Secretion and Paracrine Effects of Nitric Oxide and Interleukin-1Î². Cancer Research, 2004, 64, 1331-1337.	0.9	241
9	Notch2 is required for progression of pancreatic intraepithelial neoplasia and development of pancreatic ductal adenocarcinoma. Proceedings of the National Academy of Sciences of the United States of America, 2010, 107, 13438-13443.	7.1	190
10	Somatostatin receptor expression related to TP53 and RB1 alterations in pancreatic and extrapancreatic neuroendocrine neoplasms with a Ki67-index above 20%. Modern Pathology, 2017, 30, 587-598.	5.5	162
11	Pancreatic fibrosis associated with age and ductal papillary hyperplasia. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2005, 447, 800-805.	2.8	149
12	Intraductal papillary neoplasms of the bile duct: stepwise progression to carcinoma involves common molecular pathways. Modern Pathology, 2014, 27, 73-86.	5.5	127
13	Duct changes and K-ras mutations in the disease-free pancreas: analysis of type, age relation and spatial distribution. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 1999, 435, 461-468.	2.8	116
14	Early Requirement of Rac1 in a Mouse Model of Pancreatic Cancer. Gastroenterology, 2011, 141, 719-730.e7.	1.3	105
15	Heterozygous carriage of the alpha1-antitrypsin Pi*Z variant increases the risk to develop liver cirrhosis. Gut, 2019, 68, 1099-1107.	12.1	100
16	Pancreatic neuroendocrine carcinomas reveal a closer relationship to ductal adenocarcinomas than to neuroendocrine tumors G3. Human Pathology, 2018, 77, 70-79.	2.0	95
17	Up-regulation of L1CAM in Pancreatic Duct Cells Is Transforming Growth Factor Î²1â€“ and Slug-Dependent: Role in Malignant Transformation of Pancreatic Cancer. Cancer Research, 2009, 69, 4517-4526.	0.9	90
18	The CXCR5 Chemokine Receptor Is Expressed by Carcinoma Cells and Promotes Growth of Colon Carcinoma in the Liver. Cancer Research, 2006, 66, 9576-9582.	0.9	89

#	Article	IF	Citations
19	<i>MAFA</i> missense mutation causes familial insulinomatosis and diabetes mellitus. Proceedings of the National Academy of Sciences of the United States of America, 2018, 115, 1027-1032.	7.1	88
20	Inverse expression of somatostatin and CXCR4 chemokine receptors in gastroenteropancreatic neuroendocrine neoplasms of different malignancy. Oncotarget, 2015, 6, 27566-27579.	1.8	77
21	Expression of Lymphangiogenic Factors and Evidence of Intratumoral Lymphangiogenesis in Pancreatic Endocrine Tumors. American Journal of Pathology, 2004, 165, 1187-1197.	3.8	70
22	Comparative Characterization of Stroma Cells and Ductal Epithelium in Chronic Pancreatitis and Pancreatic Ductal Adenocarcinoma. PLoS ONE, 2014, 9, e94357.	2.5	70
23	Analysis of the Pancreatic Tumor Progression by a Quantitative Proteomic Approach and Immunhistochemical Validation. Journal of Proteome Research, 2009, 8, 1647-1656.	3.7	67
24	Glucagon Cell Hyperplasia and Neoplasia With and Without Glucagon Receptor Mutations. Journal of Clinical Endocrinology and Metabolism, 2015, 100, E783-E788.	3.6	65
25	Role of myofibroblasts in innate chemoresistance of pancreatic carcinomaâ€"Epigenetic downregulation of caspases. International Journal of Cancer, 2008, 123, 1751-1760.	5.1	64
26	The Crosstalk between Nrf2 and TGF-Î²1 in the Epithelial-Mesenchymal Transition of Pancreatic Duct Epithelial Cells. PLoS ONE, 2015, 10, e0132978.	2.5	48
27	Lymphatic spread of ductal pancreatic adenocarcinoma is independent of lymphangiogenesis. Journal of Pathology, 2005, 207, 301-312.	4.5	46
28	Chronic graft-versus-host-disease in CD34+-humanized NSG mice is associated with human susceptibility HLA haplotypes for autoimmune disease. Journal of Autoimmunity, 2015, 62, 55-66.	6.5	38
29	Therapeutic targeting of tumorâ€associated macrophages in pancreatic neuroendocrine tumors. International Journal of Cancer, 2018, 143, 1806-1816.	5.1	35
30	Lack of CCR7 expression is rate limiting for lymphatic spread of pancreatic ductal adenocarcinoma. International Journal of Cancer, 2012, 131, E371-81.	5.1	31
31	Vascular endothelial growth factor mediated angiogenic potential of pancreatic ductal carcinomas enhanced by hypoxia: Anin vitroandin vivostudy. International Journal of Cancer, 2002, 102, 592-600.	5.1	30
32	Microvessel density and angiogenesis in primary hepatic malignancies: Differential expression of CD31 and VEGFR-2 in hepatocellular carcinoma and intrahepatic cholangiocarcinoma. Pathology Research and Practice, 2018, 214, 1136-1141.	2.3	30
33	Role of BCL9L in transforming growth factor-Î² (TGF-Î²)-induced epithelial-to-mesenchymal-transition (EMT) and metastasis of pancreatic cancer. Oncotarget, 2016, 7, 73725-73738.	1.8	25
34	SDF-1/CXCR4 expression is an independent negative prognostic biomarker in patients with head and neck cancer after primary radiochemotherapy. Radiotherapy and Oncology, 2018, 126, 125-131.	0.6	24
35	Impact of surgery in patients with metastatic soft tissue sarcoma: A monocentric retrospective analysis. Journal of Surgical Oncology, 2018, 118, 167-176.	1.7	22
36	Novel prognostic markers revealed by a proteomic approach separating benign from malignant insulinomas. Modern Pathology, 2015, 28, 69-79.	5.5	20

#	Article	IF	Citations
37	Morphology of the peritoneal cavity and pathophysiological consequences. Pleura and Peritoneum, 2016, 1, 193-201.	1.2	20
38	Targeting interleukin 6 signaling by monoclonal antibody siltuximab on cholangiocarcinoma. Journal of Gastroenterology and Hepatology (Australia), 2021, 36, 1334-1345.	2.8	18
39	Terminally Modified Oligodeoxynucleotides Directed Against p53 in an Orthotopic Xenograft Model: A Novel Adjuvant Treatment Strategy for Pancreatic Ductal Carcinoma. Pancreas, 2004, 28, 1-12.	1.1	17
40	The anti-oxidative transcription factor Nuclear factor E2 related factor-2 (Nrf2) counteracts TGF-Î²1 mediated growth inhibition of pancreatic ductal epithelial cells -Nrf2 as determinant of pro-tumorigenic functions of TGF-Î²1. BMC Cancer, 2016, 16, 155.	2.6	17
41	Contrast-enhanced imaging in hepatic epithelioid hemangioendothelioma: retrospective study of 10 patients. Zeitschrift Fur Gastroenterologie, 2019, 57, 753-766.	0.5	17
42	SDF-1/CXCR4 expression in head and neck cancer and outcome after postoperative radiochemotherapy. Clinical and Translational Radiation Oncology, 2017, 5, 28-36.	1.7	16
43	miRNA dynamics in tumor-infiltrating myeloid cells modulating tumor progression in pancreatic cancer. OncoImmunology, 2016, 5, e1160181.	4.6	14
44	Combined effects of PNPLA3, TM6SF2 and HSD17B13 variants on severity of biopsy-proven non-alcoholic fatty liver disease. Hepatology International, 2021, 15, 922-933.	4.2	14
45	A Multistep High-Content Screening Approach to Identify Novel Functionally Relevant Target Genes in Pancreatic Cancer. PLoS ONE, 2015, 10, e0122946.	2.5	13
46	Immunoprofiling in Neuroendocrine Neoplasms Unveil Immunosuppressive Microenvironment. Cancers, 2020, 12, 3448.	3.7	12
47	Unraveling the Molecular Tumor-Promoting Regulation of Cofilin-1 in Pancreatic Cancer. Cancers, 2021, 13, 725.	3.7	12
48	Therapeutic effects of Argyrin F in pancreatic adenocarcinoma. Cancer Letters, 2017, 399, 20-28.	7.2	8
49	The role of integrins in primary and secondary brain tumors. Histology and Histopathology, 2016, 31, 1069-78.	0.7	8
50	The antioxidant transcription factor Nrf2 modulates the stress response and phenotype of malignant as well as premalignant pancreatic ductal epithelial cells by inducing expression of the ATF3 splicing variant Î”Zip2. Oncogene, 2019, 38, 1461-1476.	5.9	7
51	CUX1 Enhances Pancreatic Cancer Formation by Synergizing with KRAS and Inducing MEK/ERK-Dependent Proliferation. Cancers, 2021, 13, 2462.	3.7	6
52	Major histocompatibility complex class 1 (MHC1) loss among patients with glioblastoma (GBM).. Journal of Clinical Oncology, 2020, 38, e14523-e14523.	1.6	5
53	Treatment of pancreatic ductal adenocarcinoma (PDAC) by argyrin F (AF) + gemcitabine (G).. Journal of Clinical Oncology, 2016, 34, 310-310.	1.6	0
54	Solide und zystische nichtendokrine Tumoren des Pankreas. Pathologie, 2020, , 707-774.	0.0	0